The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab.
- DOI
- 10.3390/cancers16183182
- Published
- 2024 Sep 17
- Container
- Cancers
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/cancers16183182,
title = {The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab.},
author = {Guinan K and Mathurin K and Lachaine J and Roc NP and Bull SJ and Tankala D and Barakat S and Manzoor BS and Hillis C and Banerji V},
year = {2024},
journal = {Cancers},
doi = {10.3390/cancers16183182},
url = {https://doi.org/10.3390/cancers16183182}
}RIS
TY - JOUR TI - The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab. AU - Guinan K AU - Mathurin K AU - Lachaine J AU - Roc NP AU - Bull SJ AU - Tankala D AU - Barakat S AU - Manzoor BS AU - Hillis C AU - Banerji V PY - 2024 JO - Cancers DO - 10.3390/cancers16183182 UR - https://doi.org/10.3390/cancers16183182 ER -
APA
K, G., K, M., J, L., NP, R., SJ, B., D, T., S, B., BS, M., C, H., & V, B. (2024). The Economic Impact of Treatment Sequencing in Chronic Lymphocytic Leukemia in Canada Using Venetoclax plus Obinutuzumab.. Cancers. https://doi.org/10.3390/cancers16183182
Source records
- pubmed · retrieved 2026-09-26T08:49:04.792Z